Alberta Purchasing #2026RSS0058

University of Calgary seeks proprietary MRD assay materials and processing services for Multiple Myeloma research

The University of Calgary CTRC Lab is seeking proprietary minimal residual disease (MRD) assay materials and processing services to advance Multiple Myeloma research. - Government buyer: - University of Calgary, CTRC Lab, Alberta, Canada - OEMs and vendors: - Adaptive Biotechnologies Corporation (OEM) - Products/services requested: - clonoSEQ MRD assay materials (no specific part numbers or quantities provided) - clonoSEQ MRD processing services (including clonotype identification, MRD quantification, and longitudinal disease tracking) - Unique or notable requirements: - Direct award due to exclusive intellectual property protections and patents - Only Adaptive Biotechnologies' clonoSEQ assay meets the ultra-high sensitivity requirement (detecting one malignant cell among one million healthy cells) - No other supplier is authorized or capable of providing an equivalent solution - First use in Canada for research and field testing - Procurement includes both proprietary assay materials and associated processing services

Description

The University of Calgary CTRC Lab is procuring assay materials and processing services to support research involving minimal residual disease (MRD) testing in Multiple Myeloma. The contract aims to secure a service provider capable of ultra-high sensitivity detection of malignant cells. The procurement is for the clonoSEQ MRD assay materials and processing services, which are proprietary and exclusively provided by Adaptive Biotechnologies Corporation. Due to intellectual property protections, no other supplier can provide an equivalent solution. This procurement is a direct award for research and field testing purposes.

View original listing